Analysis of inactivating alterations in TSC1 and TSC2 in advanced genitourinary (GU) cancers from a real-world patient population in the Foundation Medicine genomic database
26
Jan2024
26
Jan2024
PRECISION 1: A phase 2, multicenter, open-label tumor-agnostic trial of nab-sirolimus for malignant solid tumors harboring pathogenic inactivating alterations in TSC1 and TSC2
19
Jan2024
Phase 2 study of nab-sirolimus in patients with well-differentiated and advanced/metastatic neuroendocrine tumors of the gastrointestinal tract, lung, or pancreas
19
Jan2024
Real-world analysis of patients with advanced gastrointestinal cancers harboring inactivating alterations in TSC1 and TSC2 using the Foundation Medicine genomic database
19
Jan2024
PRECISION 1: A phase 2, multicenter, open-label tumor-agnostic trial of nab-sirolimus for malignant solid tumors harboring pathogenic inactivating alterations in TSC1 and TSC2
25
Sep2022
Dr. Hehenberger served as Chief Executive Officer of Lyfebulb, Inc., a patient engagement platform, from January 2014 to March 2024. Following Lyfebulb’s acquisition by Patient Care America (PCA) in March 2024, Dr. Hehenberger serves as Chief Medical Officer of PCA and Chief Medical Officer of Lyfebulb, a Patient Care America ... Read More
05
Sep2022
Mr. Ball serves as Aadi’s Chief Technical Operations Officer, bringing 25 years of experience leading quality, manufacturing and supply chain teams in healthcare regulated industries. Most recently, Mr. Ball served as the CQO and SVP Operations at Intercept Pharmaceuticals, where he oversaw commercial product and prepared the organization to support ... Read More
15
Aug2022
Caley Castelein, M.D. has served as Chair of our board of directors since August 2021. Since February 2017, Dr. Castelein has served as a member of the board of directors of Aerpio Therapeutics, Inc., a biopharmaceutical company, which merged with Aadi Bioscience, Inc. (NASDAQ: AADI) in August 2021. Since March ... Read More